Opendata, web and dolomites

X-BONECUT SIGNED

Next generation robotic surgery: robotic vision based safe endoscopic spine surgery

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "X-BONECUT" data sheet

The following table provides information about the project.

Coordinator
DENEB MEDICAL, SL 

Organization address
address: PQUE TECNOLOGICO MIRAMON P MIKELETEGI 83 EDIFICIO
city: SAN SEBASTIAN
postcode: 20009
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 3˙004˙562 €
 EC max contribution 2˙103˙193 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-11-01   to  2021-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DENEB MEDICAL, SL ES (SAN SEBASTIAN) coordinator 2˙103˙193.00

Map

 Project objective

All surgical robotic solutions available in the market today are precise manipulators rather than robots, as none of them takes its own decisions nor does automatize any process. For surgical robotics to make the next paradigm change, the ability for the robots to take their own decisions must be developed. To take their own decisions, they need to be aware of the environment where they are working. In other words: they need to have robotic eyes. This is exactly what Deneb Medical (DM) is developing with its X Platform. This surgical robotic platform approach enables multiple market applications, for which Deneb Medical has defined a product pipeline. The first product in this pipeline is DM’s X-BoneCut. Today the most important surgical problem, is the elimination of surgical unintended damage. DM’s X-BoneCut will be a surgical robot tailored to perform endoscopic lumbar surgeries in a safe and fast way, eliminating the risk of surgical unintended damage to duramater (incidental durotomy) and nerves, reducing overall surgery time and with an easy learning curve. X-BoneCut will add to private and public health institutions up to 7B$ in value in EU and US, as it will help reduce total average direct costs to hospitals in 7B$. DM’s business model is based on the development, manufacturing and sale of the robot and its disposable. The revenue model includes the sale to the distributor of a) the robotic system b) the disposable needed to perform surgeries with it and c) the robot’s maintenance contract. DM’s strategy is to install a big number of robots and supply the disposables, so the revenue portion of the disposable will increase throughout the years. X-BoneCut is based on a DM’s already patented technology and DM knows no competitor that is developing a similar device with a similar functionality. Further DM is working on 3 additional patent applications that will help create stronger competitive advantages, not only for the short but also for the longer term.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "X-BONECUT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "X-BONECUT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Totem Spoon (2019)

Interactive Digital Signage with emotional intelligence for smart cities

Read More  

MEDIVAC (2019)

Machine learning software to design personalized neoantigen vaccines tailored to specific vaccine delivery systems

Read More  

RDNA (2019)

Empowering New Venture Growth - RDNA

Read More